Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.

Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.

Researchers at Vanderbilt University Medical Center (VUMC) have received a four-year, $6.2-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a novel panel of biomarkers to improve the diagnosis of acute heart failure (AHF).

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

Up to 25% of patients with acute heart failure (AHF) face mortality or hospital readmission within one month after being treated in the emergency department (ED).

Sean Collins, MD, MSci, professor of Emergency Medicine, has taken on new leadership roles in the Vanderbilt Coordinating Center (VCC) and the Vanderbilt Institute for Medicine and Public Health (IMPH).

A national study led by researchers at Vanderbilt University Medical Center has found that many patients who arrive at the emergency department (ED) with acute heart failure can be safely discharged with self-care guidance and frequent phone appointments, avoiding the need for hospitalization.